MA51042A - Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée - Google Patents
Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutéeInfo
- Publication number
- MA51042A MA51042A MA051042A MA51042A MA51042A MA 51042 A MA51042 A MA 51042A MA 051042 A MA051042 A MA 051042A MA 51042 A MA51042 A MA 51042A MA 51042 A MA51042 A MA 51042A
- Authority
- MA
- Morocco
- Prior art keywords
- class
- limited
- ras protein
- hla antigen
- antigenic specificity
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000016914 ras Proteins Human genes 0.000 title 1
- 108010014186 ras Proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762594244P | 2017-12-04 | 2017-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51042A true MA51042A (fr) | 2020-10-14 |
Family
ID=64949411
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051042A MA51042A (fr) | 2017-12-04 | 2018-12-03 | Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée |
| MA051043A MA51043A (fr) | 2017-12-04 | 2018-12-03 | Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051043A MA51043A (fr) | 2017-12-04 | 2018-12-03 | Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11466071B2 (fr) |
| EP (1) | EP3720478A1 (fr) |
| JP (2) | JP7385566B2 (fr) |
| KR (1) | KR20200115484A (fr) |
| CN (1) | CN111836638A (fr) |
| AU (1) | AU2018378200A1 (fr) |
| BR (1) | BR112020011111A2 (fr) |
| CA (1) | CA3084246A1 (fr) |
| CR (1) | CR20200287A (fr) |
| EA (1) | EA202091335A1 (fr) |
| IL (1) | IL275031A (fr) |
| MA (2) | MA51042A (fr) |
| MX (1) | MX2020005765A (fr) |
| SG (1) | SG11202005236QA (fr) |
| WO (1) | WO2019112941A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3635000A4 (fr) * | 2017-05-16 | 2021-04-14 | The Johns Hopkins University | Manabodies et procédés d'utilisation |
| AU2020213119A1 (en) * | 2019-01-25 | 2021-09-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant RAS |
| CA3130618A1 (fr) * | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Proteines de liaison specifiques pour des neo-antigenes ras et leurs utilisations |
| EP3760217A1 (fr) * | 2019-07-01 | 2021-01-06 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Thérapie cellulaire ou génique basée sur le récepteur de lymphocytes t cd5 spécifiques |
| CN112646024B (zh) * | 2019-10-10 | 2023-03-24 | 香雪生命科学技术（广东）有限公司 | 一种识别kras突变的t细胞受体及其编码序列 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| JP2023528112A (ja) * | 2020-02-12 | 2023-07-04 | アメリカ合衆国 | Ｇ１２ｄ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体 |
| TW202140535A (zh) * | 2020-02-14 | 2021-11-01 | 美國衛生與公眾服務部 | 針對含有g12v突變之ras之hla第i類限制性t細胞受體 |
| US20230159614A1 (en) * | 2020-02-26 | 2023-05-25 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class ii-restricted t cell receptors against ras with g12v mutation |
| KR20230084524A (ko) * | 2020-10-02 | 2023-06-13 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | G13d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 dq t 세포 수용체 |
| KR102488353B1 (ko) * | 2020-10-08 | 2023-01-12 | 부산대학교 산학협력단 | 돌연변이 kras를 표적하는 펩타이드 및 이의 용도 |
| AU2022227085A1 (en) | 2021-02-25 | 2023-09-14 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| EP4347639A1 (fr) * | 2021-05-25 | 2024-04-10 | Memorial Sloan Kettering Cancer Center | Récepteurs de lymphocytes t ciblant les mutations ras et leurs utilisations |
| WO2023139257A1 (fr) | 2022-01-21 | 2023-07-27 | T-Knife Gmbh | Construction reconnaissant un antigène se liant à un peptide spécifique avec une affinité déterminable et récepteur de lymphocytes t ayant une spécificité antigénique pour kras, séquence d'acide nucléique correspondante, vecteur, cellule hôte, composition pharmaceutique et kit |
| WO2023150562A1 (fr) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Méthodes d'activation et d'expansion de lymphocytes t |
| CN117264043B (zh) * | 2022-06-14 | 2024-05-10 | 上海镔铁生物科技有限责任公司 | 靶向kras g12v突变多肽的t细胞受体及其用途 |
| CN115960204B (zh) * | 2022-11-04 | 2023-08-25 | 新景智源生物科技(苏州)有限公司 | Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1545204T3 (en) | 2002-09-06 | 2016-11-14 | The Government Of The Us Secretary Dept Of Health And Human Services | Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US9345748B2 (en) * | 2010-09-21 | 2016-05-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-SSX-2 T cell receptors and related materials and methods of use |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| JP6863893B2 (ja) * | 2014-11-26 | 2021-04-21 | アメリカ合衆国 | 抗突然変異ｋｒａｓ ｔ細胞受容体 |
| CN115073583A (zh) | 2015-09-15 | 2022-09-20 | 美国卫生和人力服务部 | 识别hla-cw8限制性突变kras的t细胞受体 |
| EP3394092A1 (fr) * | 2015-12-23 | 2018-10-31 | Fred Hutchinson Cancer Research Center | Récepteurs des cellules t à forte affinité et leurs utilisations |
| DK3394247T3 (da) | 2015-12-23 | 2021-04-12 | Medigene Immunotherapies Gmbh | Ny generering af antigen-specifikke tcr'er |
| US20210052642A1 (en) * | 2017-12-04 | 2021-02-25 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of enriching cell populations for cancer-specific t cells using in vitro stimulation of memory t cells |
-
2018
- 2018-12-03 JP JP2020530325A patent/JP7385566B2/ja active Active
- 2018-12-03 CA CA3084246A patent/CA3084246A1/fr active Pending
- 2018-12-03 MX MX2020005765A patent/MX2020005765A/es unknown
- 2018-12-03 WO PCT/US2018/063581 patent/WO2019112941A1/fr active Application Filing
- 2018-12-03 US US16/769,144 patent/US11466071B2/en active Active
- 2018-12-03 EP EP18830062.8A patent/EP3720478A1/fr active Pending
- 2018-12-03 AU AU2018378200A patent/AU2018378200A1/en active Pending
- 2018-12-03 CR CR20200287A patent/CR20200287A/es unknown
- 2018-12-03 KR KR1020207019185A patent/KR20200115484A/ko not_active Application Discontinuation
- 2018-12-03 MA MA051042A patent/MA51042A/fr unknown
- 2018-12-03 BR BR112020011111-2A patent/BR112020011111A2/pt unknown
- 2018-12-03 MA MA051043A patent/MA51043A/fr unknown
- 2018-12-03 SG SG11202005236QA patent/SG11202005236QA/en unknown
- 2018-12-03 CN CN201880087270.7A patent/CN111836638A/zh active Pending
- 2018-12-03 EA EA202091335A patent/EA202091335A1/ru unknown
-
2020
- 2020-06-01 IL IL275031A patent/IL275031A/en unknown
-
2022
- 2022-09-12 US US17/931,391 patent/US20230026180A1/en active Pending
-
2023
- 2023-08-18 JP JP2023133670A patent/JP2023175703A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202005236QA (en) | 2020-07-29 |
| JP2023175703A (ja) | 2023-12-12 |
| CN111836638A (zh) | 2020-10-27 |
| EA202091335A1 (ru) | 2020-10-15 |
| US11466071B2 (en) | 2022-10-11 |
| MA51043A (fr) | 2020-10-14 |
| JP2021505136A (ja) | 2021-02-18 |
| KR20200115484A (ko) | 2020-10-07 |
| IL275031A (en) | 2020-07-30 |
| WO2019112941A1 (fr) | 2019-06-13 |
| CR20200287A (es) | 2020-11-11 |
| US20230026180A1 (en) | 2023-01-26 |
| MX2020005765A (es) | 2020-09-25 |
| JP7385566B2 (ja) | 2023-11-22 |
| BR112020011111A2 (pt) | 2020-11-17 |
| US20210079058A1 (en) | 2021-03-18 |
| AU2018378200A1 (en) | 2020-07-02 |
| CA3084246A1 (fr) | 2019-06-13 |
| EP3720478A1 (fr) | 2020-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51042A (fr) | Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée | |
| CY1121539T1 (el) | Ειδικοι για κλαυδiνη-6 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων | |
| CY1125008T1 (el) | Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| CY1122188T1 (el) | Θεραπευτικη αντιμετωπιση της προοδευτικης οστεοποιους ινοδυσπλασιας | |
| CY1122804T1 (el) | Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα) | |
| SG11202101685XA (en) | Bcma chimeric antigen receptor based on single domain antibody and use thereof | |
| MA49990A (fr) | Récepteurs de liaison à l'antigène améliorés | |
| NZ733025A (en) | Bcma chimeric antigen receptors | |
| MA46952A (fr) | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet | |
| PE20170125A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
| AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| EA201692504A1 (ru) | Триспецифичные связывающие молекулы и способы их применения | |
| AR099812A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr | |
| JP2016029056A5 (fr) | ||
| CO2019013654A2 (es) | Receptores de antígenos quiméricos que se dirigen a flt3 | |
| BR112015022260A2 (pt) | anticorpo monoclonal, polinucleotídeo, composição farmacêutica, fragmento isolado de tau, uso de um anticorpo, método de triagem de um agente e ácido nucleico | |
| PE20140612A1 (es) | Estratificaciones a base de bcma y terapia para pacientes con mieloma multiple | |
| BR112019002579A2 (pt) | anticorpos biespecíficos fab monovalentes, assimétricos e tandem | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| NZ630433A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
| RU2017129721A (ru) | АНТИТЕЛА ПРОТИВ αβTCR | |
| CY1124141T1 (el) | Anti-cd28 εξανθρωπισμενα αντισωματα τυποποιημενα για χορηγηση σε ανθρωπους | |
| IL284091A (en) | Antibodies neutralize the type 2 immunoglobulin-like leukocyte receptor | |
| UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ |